Cargando…

Prevalence and associated risk factors of acne relapse among Saudi acne vulgaris patients using isotretinoin

BACKGROUND: Acne vulgaris is a self-limiting condition that may affect the patients quality of life. The most efficacious treatment of choice for acne is isotretinoin. However, adverse effects and relapse of acne after completing an isotretinoin course pose major hurdles for treatment compliance and...

Descripción completa

Detalles Bibliográficos
Autores principales: SA, Alshammari, Y, Alamri, AM, Alanazi, SA, Almuhanna, L, Pinjabi, NA, Alsnaidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078551/
https://www.ncbi.nlm.nih.gov/pubmed/32194340
http://dx.doi.org/10.1016/j.jsps.2020.01.019
_version_ 1783507643402289152
author SA, Alshammari
Y, Alamri
AM, Alanazi
SA, Almuhanna
L, Pinjabi
NA, Alsnaidi
author_facet SA, Alshammari
Y, Alamri
AM, Alanazi
SA, Almuhanna
L, Pinjabi
NA, Alsnaidi
author_sort SA, Alshammari
collection PubMed
description BACKGROUND: Acne vulgaris is a self-limiting condition that may affect the patients quality of life. The most efficacious treatment of choice for acne is isotretinoin. However, adverse effects and relapse of acne after completing an isotretinoin course pose major hurdles for treatment compliance and adherence. METHOD: The authors conducted a cross-sectional study using a self-administered questionnaire. The prevalence and risk factors associated with the relapse of acne following isotretinoin use among Saudi patients were assessed. In addition, the reasons for discontinuing treatment, extent of awareness about isotretinoin use-associated teratogenicity, side effects such as liver enzymes impairments, dry mouth, skin, eyes, and the number of people using isotretinoin without a prescription were determined. RESULTS: Four hundred and twenty seven acne vulgaris patients (mean age: 25.0 years, female: 83%) were included in this study. Of the 57% subjects who used isotretinoin, 45.12% patients showed relapse. The daily dose of oral isotretinoin of 20 and 40 mg/day was taken by 80% in both group of patients, and the mean duration of isotretinoin use was 7.15(±4.5) months. Those patients who were taking higher doses of oral isotretinoin reported having more relapses. Although a majority of patients received the medication through prescription, unfortunately, they were not aware of relapse and side effects. CONCLUSION: Almost half of the patients showed relapse of acne after using isotretinoin. A lack of understanding regarding relapse and side effects indicates a need to improve public and professional awareness of isotretinoin.
format Online
Article
Text
id pubmed-7078551
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70785512020-03-19 Prevalence and associated risk factors of acne relapse among Saudi acne vulgaris patients using isotretinoin SA, Alshammari Y, Alamri AM, Alanazi SA, Almuhanna L, Pinjabi NA, Alsnaidi Saudi Pharm J Article BACKGROUND: Acne vulgaris is a self-limiting condition that may affect the patients quality of life. The most efficacious treatment of choice for acne is isotretinoin. However, adverse effects and relapse of acne after completing an isotretinoin course pose major hurdles for treatment compliance and adherence. METHOD: The authors conducted a cross-sectional study using a self-administered questionnaire. The prevalence and risk factors associated with the relapse of acne following isotretinoin use among Saudi patients were assessed. In addition, the reasons for discontinuing treatment, extent of awareness about isotretinoin use-associated teratogenicity, side effects such as liver enzymes impairments, dry mouth, skin, eyes, and the number of people using isotretinoin without a prescription were determined. RESULTS: Four hundred and twenty seven acne vulgaris patients (mean age: 25.0 years, female: 83%) were included in this study. Of the 57% subjects who used isotretinoin, 45.12% patients showed relapse. The daily dose of oral isotretinoin of 20 and 40 mg/day was taken by 80% in both group of patients, and the mean duration of isotretinoin use was 7.15(±4.5) months. Those patients who were taking higher doses of oral isotretinoin reported having more relapses. Although a majority of patients received the medication through prescription, unfortunately, they were not aware of relapse and side effects. CONCLUSION: Almost half of the patients showed relapse of acne after using isotretinoin. A lack of understanding regarding relapse and side effects indicates a need to improve public and professional awareness of isotretinoin. Elsevier 2020-03 2020-02-10 /pmc/articles/PMC7078551/ /pubmed/32194340 http://dx.doi.org/10.1016/j.jsps.2020.01.019 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
SA, Alshammari
Y, Alamri
AM, Alanazi
SA, Almuhanna
L, Pinjabi
NA, Alsnaidi
Prevalence and associated risk factors of acne relapse among Saudi acne vulgaris patients using isotretinoin
title Prevalence and associated risk factors of acne relapse among Saudi acne vulgaris patients using isotretinoin
title_full Prevalence and associated risk factors of acne relapse among Saudi acne vulgaris patients using isotretinoin
title_fullStr Prevalence and associated risk factors of acne relapse among Saudi acne vulgaris patients using isotretinoin
title_full_unstemmed Prevalence and associated risk factors of acne relapse among Saudi acne vulgaris patients using isotretinoin
title_short Prevalence and associated risk factors of acne relapse among Saudi acne vulgaris patients using isotretinoin
title_sort prevalence and associated risk factors of acne relapse among saudi acne vulgaris patients using isotretinoin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078551/
https://www.ncbi.nlm.nih.gov/pubmed/32194340
http://dx.doi.org/10.1016/j.jsps.2020.01.019
work_keys_str_mv AT saalshammari prevalenceandassociatedriskfactorsofacnerelapseamongsaudiacnevulgarispatientsusingisotretinoin
AT yalamri prevalenceandassociatedriskfactorsofacnerelapseamongsaudiacnevulgarispatientsusingisotretinoin
AT amalanazi prevalenceandassociatedriskfactorsofacnerelapseamongsaudiacnevulgarispatientsusingisotretinoin
AT saalmuhanna prevalenceandassociatedriskfactorsofacnerelapseamongsaudiacnevulgarispatientsusingisotretinoin
AT lpinjabi prevalenceandassociatedriskfactorsofacnerelapseamongsaudiacnevulgarispatientsusingisotretinoin
AT naalsnaidi prevalenceandassociatedriskfactorsofacnerelapseamongsaudiacnevulgarispatientsusingisotretinoin